Dendritic Cell Myeloma Fusions Stimulate Anti-Tumor Immunity: Results from Pre-Clinical Studies and a Clinical Trial.
David Avigan(Beth Israel Deaconess Medical Center), Donald Küfe(Dana-Farber Cancer Institute), Robin Joyce(Beth Israel Deaconess Medical Center), Ken Miller(Beth Israel Deaconess Medical Center), Lynne Uhl(Hadassah Medical Center), Paul G. Richardson(Harvard University), Nikhil C. Munshi(Dana-Farber Cancer Institute), Jacalyn Rosenblatt(Beth Israel Deaconess Medical Center), P. Forino(Beth Israel Deaconess Medical Center), JoAnn Proper(Dana-Farber Cancer Institute), Baldev Vasir(Beth Israel Deaconess Medical Center), Marisa Villaroel(Beth Israel Deaconess Medical Center), Zekui Wu(Dana-Farber Cancer Institute), Nancy Gillombardo(Beth Israel Deaconess Medical Center), James D. Levine(Beth Israel Deaconess Medical Center), Therese Desliva(Beth Israel Deaconess Medical Center)
Cited by 5
Related Papers
Signatures of mutational processes in human cancer
|Nature|2013|10.1k
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
|New England Journal of Medicine|2003|2.6k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k